Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Herrera, A. F.
17046  Ergebnisse:
Personensuche X
?
1

On the Suitability of Fuzzy Rule-Based Classification Syste..:

Saez, J. ; Luengo, J. ; Herrera, F.
IEEE Transactions on Fuzzy Systems.  , 2024
Link: https://doi.org/10.1109/..
 
?
2

101P Progression-free survival is an acceptable surrogate e..:

Yarza, R. ; Kountouri, M. ; Costa Guedes, H.M....
Immuno-Oncology and Technology.  20 (2023)  - p. 100573 , 2023
Link: https://doi.org/10.1016/..
 
?
3

A phase II, open‐label, multicenter study of capivasertib, ..:

Hodson, D. ; Shouse, G. ; Shin, H....
Hematological Oncology.  41 (2023)  S2 - p. 562-564 , 2023
Link: https://doi.org/10.1002/..
 
?
4

An open‐label phase 1/2 study of favezelimab plus pembroliz..:

Lavie, D. ; Johnson, N. ; Borchmann, P....
Hematological Oncology.  41 (2023)  S2 - p. 364-366 , 2023
Link: https://doi.org/10.1002/..
 
?
5

CIRCULATING TUMOR DNA (CTDNA) STATUS AND CLINICAL OUTCOMES ..:

Herrera, A. F. ; Tracy, S. ; Sehn, L. H....
Hematological Oncology.  41 (2023)  S2 - p. 175-177 , 2023
Link: https://doi.org/10.1002/..
 
?
6

Is unicentric familial papillary thyroid microcarcinoma dif..:

Ríos, A. ; Ruiz-Pardo, J. ; Balaguer-Román, A....
Endocrine.  82 (2023)  3 - p. 613-621 , 2023
Link: https://doi.org/10.1007/..
 
?
7

SP-0356 Low dose radiotherapy reverses resistance to immuno..:

Herrera, F.
Radiotherapy and Oncology.  182 (2023)  - p. S275 , 2023
Link: https://doi.org/10.1016/..
 
?
8

FAVEZELIMAB PLUS PEMBROLIZUMAB IN ANTI–PD‐1–REFRACTORY CLAS..:

Armand, P. ; Zinzani, P. L. ; Timmerman, J....
Hematological Oncology.  41 (2023)  S2 - p. 163-165 , 2023
Link: https://doi.org/10.1002/..
 
?
9

NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARE..:

Herrera, A. F. ; LeBlanc, M. ; Castellino, S. M....
Hematological Oncology.  41 (2023)  S2 - p. 33-35 , 2023
Link: https://doi.org/10.1002/..
 
?
10

IMMUNE CONTEXTURE ANALYSIS IN POLARIX SUGGESTS RESPONSE TO ..:

Morschhauser, F. ; Hatzi, K. ; Lenz, G....
Hematological Oncology.  41 (2023)  S2 - p. 223-225 , 2023
Link: https://doi.org/10.1002/..
 
?
11

P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION ..:

Kuruvilla, J. ; Armand, P. ; Herrera, A. F....
HemaSphere.  6 (2022)  - p. 1236-1237 , 2022
Link: https://doi.org/10.1097/..
 
?
12

P472: THE FLT3-ITD RECEPTOR CAN PROMOTE PROTEIN FOLDING IN ..:

Turos Cabal, M. ; Sánchez Sánchez, A. M. ; Puente Moncada, N....
HemaSphere.  6 (2022)  - p. 371-372 , 2022
Link: https://doi.org/10.1097/..
 
?
13

Biological behavior of familial papillary thyroid microcarc..:

Ríos, A. ; Rodríguez, M. A. ; Puñal, J. A....
Langenbeck's Archives of Surgery.  407 (2022)  8 - p. 3631-3642 , 2022
Link: https://doi.org/10.1007/..
 
?
14

P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKA..:

Herrera, A. F. ; Lavie, D. ; Johnson, N. A....
HemaSphere.  6 (2022)  - p. 977-978 , 2022
Link: https://doi.org/10.1097/..
 
?
15

S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN..:

Carlo-Stella, C. ; Ansell, S. ; Zinzani, P. L...
HemaSphere.  6 (2022)  - p. 102-103 , 2022
Link: https://doi.org/10.1097/..
 
1-15